| Assessment Status | Rapid Review complete |
| HTA ID | 24014 |
| Drug | Budesonide |
| Brand | Jorveza® |
| Indication | For the treatment of eosinophilic oesophagitis in adults (older than 18 years of age). |
| Assessment Process | |
| Rapid review commissioned | 15/05/2024 |
| Rapid review completed | 07/06/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of budesonide compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
| Full pharmacoeconomic assessment commissioned by HSE | 25/06/2024 |
